PHC is a subsidiary of PHC Group*1, a global healthcare company that develops, manufactures, sells, and services solutions across the business domains of d...
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assay...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that it has entered into an agreement ("the Agr...
Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., "Cellusion") announced that our research collaborator, Dr. Shigeto Shimmura, Professor of Fujita Health Univer...
ncyte (Nasdaq:INCY) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre® (pemigatinib), a selective fi...
Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from Astellas Acquiring leading global echinocandin, one of three...
© 2025 Biopharma Boardroom. All Rights Reserved.
